Achondroplasia Market to Grow at ~11% CAGR Through 2036 Across the 7MM | DelveInsight

DelveInsight's "Achondroplasia Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Achondroplasia, historical and forecasted epidemiology, as well as the Achondroplasia market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Achondroplasia Market Report @ https://www.delveinsight.com/report-store/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Achondroplasia Market Report
• In May 2026, at the Pediatric Endocrine Society's 2026 Annual Meeting, BioMarin presented new long-term data on Voxzogo (vosoritide) for children with achondroplasia, showing positive effects on arm span, bone health, and overall growth proportionality, with long-term therapy well-tolerated and not compromising bone mineral density.
• In March 2026, RIBOMIC announced the summary report on the Phase II clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in paediatric patients with achondroplasia.
• In March 2026, RIBOMIC submitted an IND application for a Phase III clinical trial in Japan to the PMDA for umedaptanib pegol in pediatric patients (ages 2 to 14) with achondroplasia.
• In February 2026, BridgeBio Pharma announced positive topline results from the global Phase III (PROPEL 3) study of oral infigratinib in children with achondroplasia, meeting the primary endpoint of change in annualized height velocity (AHV) at Week 52 (p is lower than 0.0001).
• The Achondroplasia Market Size was found to be ~USD 600 million in the leading markets (the United States, EU4, the United Kingdom, and Japan) in 2025.
• The Achondroplasia market is projected to grow at a CAGR of ~11% between 2026 and 2036 across the 7MM.
• The Achondroplasia treatment paradigm is shifting from supportive care toward targeted, disease-modifying therapies addressing underlying FGFR3 pathway dysregulation, driven by agents such as Vosoritide (VOXZOGO) and Navepegritide; TransCon CNP (YUVIWEL).
• The total diagnosed prevalent cases of Achondroplasia in the 7MM were approximately 28,500 in 2025, with the US accounting for the highest share.
• Among the EU4, France accounted for the highest number of diagnosed prevalent cases of Achondroplasia, followed by Germany, whereas Spain accounted for the lowest number of cases in 2025.
• A slight male predominance and earlier onset of Achondroplasia were observed, underscoring the importance of early diagnosis and continuous monitoring.
• The Achondroplasia Companies include Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC, and others.
• Promising Achondroplasia Therapies include Infigratinib (BBP-831/BGJ398), RBM-007 (umedaptanib pegol), BMN 333, and others.

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Achondroplasia?
Achondroplasia is the most common form of disproportionate short stature, caused by a genetic mutation affecting bone growth and development, particularly in the long bones. It typically presents at birth and is characterized by shortened limbs, a relatively normal trunk, and distinctive facial features. Intelligence and life expectancy are generally normal, though individuals may experience complications such as spinal stenosis, respiratory issues, and joint problems, especially in more severe cases. Achondroplasia is primarily caused by mutations in the FGFR3 gene that limit cartilage conversion to bone. Diagnosis relies on clinical evaluation and genetic testing, often at birth or during prenatal screening, with characteristic physical features raising suspicion, imaging supporting the diagnosis through typical skeletal changes, and genetic testing confirming FGFR3 mutations.

Achondroplasia Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Achondroplasia
• Gender-specific Diagnosed Prevalent Cases of Achondroplasia
• Total Treated Cases of Achondroplasia

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ https://www.delveinsight.com/report-store/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Achondroplasia Approved Therapies
• Navepegritide; TransCon CNP (YUVIWEL): Ascendis Pharma
YUVIWEL is a long-acting prodrug of C-type natriuretic peptide (CNP) designed to address the underlying cause of achondroplasia. It works by counteracting the overactive FGFR3 signaling pathway that normally inhibits bone growth, restoring balance in growth plate activity. Using TransCon technology, it provides sustained release of active CNP, enabling continuous stimulation of chondrocyte proliferation and differentiation, promoting more normalized endochondral bone growth. It is marketed in the US as of 2026.

• Vosoritide (VOXZOGO): BioMarin Pharmaceutical
VOXZOGO is a CNP analog that binds to natriuretic peptide receptor-B (NPR-B) and inhibits the overactive FGFR3 signaling pathway that suppresses bone growth, restoring normal growth plate function by promoting chondrocyte proliferation and differentiation. Unlike long-acting prodrugs, vosoritide is a short-acting therapy requiring daily administration. It is marketed in the US (2021), EU (2021), and Japan (2022).

Achondroplasia Pipeline Analysis
• Infigratinib (BBP-831/BGJ398): QED Therapeutics (BridgeBio)/Novartis/Kyowa Kirin
Infigratinib is an oral, selective FGFR1-3 tyrosine kinase inhibitor targeting the underlying genetic driver of Achondroplasia by directly inhibiting the overactive FGFR3 signaling pathway responsible for impaired bone growth, restoring downstream signaling balance in growth plate chondrocytes and aiming to normalize endochondral ossification. It is currently in Phase II.

• RBM-007 (umedaptanib pegol): RIBOMIC
RBM-007 is a PEGylated anti-FGF2 aptamer targeting fibroblast growth factor 2 (FGF2), a key regulator of abnormal bone growth signaling in Achondroplasia. By binding to and inhibiting FGF2, it aims to modulate downstream pathways associated with impaired chondrocyte proliferation and differentiation, restoring more balanced endochondral bone growth with high specificity. It is currently in Phase II.

• BMN 333: BioMarin Pharmaceutical
BMN 333 is a CNP analog targeting the FGFR3 pathway, currently in Phase II.

Achondroplasia Companies
Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC, and others

Discover more about therapies set to grab major Achondroplasia market share @ https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Achondroplasia Market Outlook
The Achondroplasia market is undergoing a significant transformation, shifting from a historically supportive care-focused approach toward targeted, disease-modifying therapies that address the underlying FGFR3-driven pathology. The approval and uptake of CNP analogs such as VOXZOGO (vosoritide) have established the first wave of mechanism-based treatment, while next-generation agents like TransCon CNP (navepegritide) aim to improve convenience and sustained efficacy through prolonged exposure. Emerging therapies such as Infigratinib highlight a growing focus on directly modulating FGFR3 signaling, further diversifying the therapeutic landscape.
With continued advancement of late-stage pipeline candidates, including long-acting CNP formulations and oral FGFR inhibitors, the achondroplasia treatment landscape is becoming increasingly competitive and innovation-driven. The United States represents the largest market, driven by higher diagnosis rates, strong access to specialty care, favorable reimbursement frameworks, and increasing awareness among clinicians and caregivers, followed by Europe and Japan. Improved genetic testing and early diagnosis are also contributing to greater treatment uptake.
In 2025, the 7MM achondroplasia market reached an estimated USD 600 million, led by the United States, which dominated with the largest share. The market is evolving as the treatment paradigm shifts from supportive and symptomatic management toward targeted disease-modifying therapies, with CNP analogs such as vosoritide and long-acting formulations like navepegritide (TransCon CNP) gaining traction due to their ability to address underlying FGFR3 pathway dysregulation. Regional market dynamics indicate the United States leads in revenue generation, while Europe and Japan are witnessing steady growth, driven by improved diagnosis rates, increasing awareness of genetic disorders, and expanding access to novel targeted therapies.

Scope of the Achondroplasia Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: North America (US); Europe (Germany, France, Italy, Spain, UK); Asia-Pacific (Japan)
• Achondroplasia Market CAGR: ~11% (2026-2036)
• Achondroplasia Companies: Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC, and others
• Achondroplasia Therapies: Navepegritide; TransCon CNP (YUVIWEL), Vosoritide (VOXZOGO), Infigratinib (BBP-831/BGJ398), RBM-007 (umedaptanib pegol), BMN 333, and others
• Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and emerging therapies
• Achondroplasia Market Dynamics: Achondroplasia market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Achondroplasia Unmet Needs, KOL's views, Analyst's views, Achondroplasia Market Access and Reimbursement

To know more about Achondroplasia companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/achondroplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology of Achondroplasia
6. Achondroplasia Market Overview at a Glance
7. Disease Background and Overview of Achondroplasia
8. Treatment
9. Epidemiology and Patient Population of Achondroplasia
10. Patient Journey of Achondroplasia
11. Marketed Therapies
12. Emerging Drugs
13. Achondroplasia: 7MM Analysis
14. Unmet Needs of Achondroplasia
15. SWOT Analysis of Achondroplasia
16. KOL Views of Achondroplasia
17. Market Access and Reimbursement of Achondroplasia
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.